title: The impact of comorbid depression on adherence to therapy for multiple sclerosis.
abstract: Objective. Examine the impact of comorbid depression on adherence to disease-modifying therapy (DMT) for multiple sclerosis (MS). Methods. A retrospective database was used to identify patients with MS treated with a DMT. Patients with MS and comorbid depression were matched to patients with MS only. Adherence to DMT was proxied by the medication possession ratio (MPR) and multivariate regressions were used to examine the association between comorbid depression and adherence to DMT. Results. Patients with comorbid depression had a 10 point lower MPR (P < 0.01) and were less likely to achieve a MPR of at least 80% (odds ratio (OR) = 0.55; 95% confidence interval (CI) 0.42-0.74) than those without depression. While treatment with an antidepressant generally had no significant impact on the likelihood of achieving an MPR threshold of 80% (OR = 1.32; 95% CI 0.50-3.48), adherence to antidepressant therapy guidelines were associated with improved adherence to DMT therapy. Conclusions. MS patients with comorbid depression were approximately half as likely to be adherent to their DMT relative to patients with MS without depression. Although treatment with antidepressant therapy generally did not improve the likelihood of adherence, treatment with antidepressants for at least 6 months was associated with better adherence to DMT.
authors.affiliation: Medical Affairs, Teva Pharmaceuticals, 901 East 104th Street, Suite 900, Kansas City, MO 64131, USA.
authors.forename: M
authors.initials: M
authors.lastname: Tarrants
authors.forename: M
authors.initials: M
authors.lastname: Oleen-Burkey
authors.forename: J
authors.initials: J
authors.lastname: Castelli-Haley
authors.forename: M J
authors.initials: MJ
authors.lastname: Lage
references.citation: J Rehabil Res Dev. 2002 Mar-Apr;39(2):273-85
references.pmid: 12051470
references.citation: Ann Pharmacother. 2009 Jan;43(1):36-44
references.pmid: 19126828
references.citation: J Neurol. 2009 Apr;256(4):568-76
references.pmid: 19444532
references.citation: Arch Intern Med. 2005 Nov 28;165(21):2508-13
references.pmid: 16314548
references.citation: Mult Scler. 1998 Oct;4(5):419-25
references.pmid: 9839302
references.citation: BMC Health Serv Res. 2003 Sep 02;3(1):17
references.pmid: 12952552
references.citation: Med Care. 2007 Dec;45(12):1210-5
references.pmid: 18007172
references.citation: Expert Opin Drug Deliv. 2009 Sep;6(9):995-1002
references.pmid: 19637982
references.citation: Ann Intern Med. 2008 Nov 18;149(10):725-33
references.pmid: 19017591
references.citation: J Behav Med. 2010 Jun;33(3):219-27
references.pmid: 20127401
references.citation: Mult Scler. 2009 Mar;15(3):385-92
references.pmid: 19153176
references.citation: Arch Neurol. 1984 Oct;41(10):1067-9
references.pmid: 6477214
references.citation: Breast Cancer Res Treat. 2011 Jan;125(1):191-200
references.pmid: 20495864
references.citation: Eur Heart J. 1991 Sep;12(9):959-64
references.pmid: 1936008
references.citation: Med Clin North Am. 2009 Mar;93(2):451-76, ix-x
references.pmid: 19272518
references.citation: Am J Manag Care. 2008 Dec;14(12):801-9
references.pmid: 19067497
references.citation: Curr Med Res Opin. 2010 Oct;26(10):2475-84
references.pmid: 20825269
references.citation: Psychosom Med. 2003 Jul-Aug;65(4):508-10
references.pmid: 12883097
references.citation: J Clin Epidemiol. 1992 Jun;45(6):613-9
references.pmid: 1607900
references.citation: Psychiatr Serv. 2010 Dec;61(12):1239-47
references.pmid: 21123409
references.citation: Neuropsychiatr Dis Treat. 2009;5:261-6
references.pmid: 19557120
references.citation: J Hypertens. 2010 Sep;28(9):1785-95
references.pmid: 20531223
references.citation: Postgrad Med. 2010 Mar;122(2):112-20
references.pmid: 20203462
references.citation: Psychosom Med. 2001 Jul-Aug;63(4):619-30
references.pmid: 11485116
references.citation: Arch Intern Med. 2000 May 8;160(9):1354-60
references.pmid: 10809041
references.citation: Circulation. 2002 Mar 5;105(9):1049-53
references.pmid: 11877353
references.citation: Psychosom Med. 2000 Nov-Dec;62(6):790-5
references.pmid: 11138998
references.citation: Value Health. 2008 Jan-Feb;11(1):44-7
references.pmid: 18237359
references.citation: Popul Health Manag. 2009 Feb;12(1):25-30
references.pmid: 19216676
references.citation: Methods Inf Med. 1993 Nov;32(5):382-7
references.pmid: 8295545
references.citation: J Manag Care Pharm. 2007 Jan-Feb;13(1):44-52
references.pmid: 17269836
references.citation: Pharmacoeconomics. 2010;28(5):363-79
references.pmid: 20402540
references.citation: Arch Phys Med Rehabil. 2005 May;86(5):1065-9
references.pmid: 15895361
references.citation: Am J Cardiol. 2010 May 15;105(10):1495-501
references.pmid: 20451702
references.citation: Mult Scler. 2010 Jan;16(1):112-20
references.pmid: 19995835
references.citation: Arch Gen Psychiatry. 2003 Jun;60(6):627-36
references.pmid: 12796226
references.citation: Am Heart J. 1999 Sep;138(3 Pt 1):549-54
references.pmid: 10467207
references.citation: Neurology. 1996 Mar;46(3):628-32
references.pmid: 8618657